The Avandia (rosiglitazone) debate will heat up again now that FDA will loosen its restrictions

January 2014

The Avandia (rosiglitazone) debate will heat up again now that FDA will loosen its restrictions.

This decision is based on a reanalysis of an older study that suggests Avandia DOES NOT increase cardiovascular risk.

But experts warn that reanalyzing a flawed study doesn't make it valid...and other studies DO suggest Avandia increases CV risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote